- Stocks
- Healthcare
- NASDAQ: BMRN

Price (delayed)

$77.04

Market cap

$14.08B

P/E Ratio

17.55

Dividend/share

N/A

EPS

$4.39

Enterprise value

$14.49B

BMRN's quick ratio has surged by 125% year-on-year and by 12% since the previous quarter

BMRN's P/E is 70% below its last 4 quarters average of 57.6

The debt is up by 26% year-on-year

BMRN's gross margin is down by 10% year-on-year

What are the main financial stats of BMRN

Market
Valuations
Earnings

Shares outstanding

182.74M

Market cap

$14.08B

Enterprise value

$14.49B

Price to earnings (P/E)

17.55

Price to book (P/B)

3.37

Price to sales (P/S)

7.59

EV/EBIT

N/A

EV/EBITDA

1,119.32

EV/Sales

7.85

Revenue

$1.84B

EBIT

-$94.25M

EBITDA

$12.94M

Free cash flow

$114.81M

Per share
Balance sheet
Liquidity

EPS

$4.39

Free cash flow per share

$0.63

Book value per share

$22.89

Revenue per share

$10.15

TBVPS

$28.62

Total assets

$5.81B

Total liabilities

$1.64B

Debt

$1.08B

Equity

$4.16B

Working capital

$1.86B

Debt to equity

0.26

Current ratio

5.32

Quick ratio

3.45

Net debt/EBITDA

31.59

Margins
Efficiency
Dividend

EBITDA margin

0.7%

Gross margin

71.1%

Net margin

43.1%

Operating margin

-6.3%

Return on assets

13.8%

Return on equity

20.4%

Return on invested capital

-1.9%

Return on capital employed

-1.8%

Return on sales

-5.1%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Biomarin Pharmaceutical stock price performed over time

Intraday

-1.81%

1 week

-2.28%

1 month

-6.71%

1 year

-38.12%

YTD

-12.15%

QTD

-7.67%

How have Biomarin Pharmaceutical's revenue and profit performed over time

Revenue

$1.84B

Gross profit

$1.31B

Operating income

-$116.64M

Net income

$795.09M

Gross margin

71.1%

Net margin

43.1%

BMRN's gross margin is down by 10% year-on-year

Biomarin Pharmaceutical's gross profit has decreased by 8% YoY

The net margin is down by 7% since the previous quarter

The net income has declined by 7% since the previous quarter

What is Biomarin Pharmaceutical's growth rate over time

What is Biomarin Pharmaceutical stock price valuation

P/E

17.55

P/B

3.37

P/S

7.59

EV/EBIT

N/A

EV/EBITDA

1,119.32

EV/Sales

7.85

BMRN's P/E is 70% below its last 4 quarters average of 57.6

Biomarin Pharmaceutical's EPS has decreased by 8% QoQ

The stock's price to book (P/B) is 34% less than its 5-year quarterly average of 5.1 and 23% less than its last 4 quarters average of 4.4

The equity has grown by 28% YoY

BMRN's price to sales (P/S) is 28% less than its 5-year quarterly average of 10.6 and 15% less than its last 4 quarters average of 8.9

The revenue has grown by 2.2% YoY

How efficient is Biomarin Pharmaceutical business performance

Biomarin Pharmaceutical's ROIC has plunged by 186% YoY

The ROE has contracted by 13% from the previous quarter

BMRN's return on assets is down by 12% since the previous quarter

What is BMRN's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for BMRN.

How did Biomarin Pharmaceutical financials performed over time

BMRN's quick ratio has surged by 125% year-on-year and by 12% since the previous quarter

The company's current ratio has surged by 106% YoY and by 12% QoQ

The debt is 74% smaller than the equity

The equity has grown by 28% YoY

The debt is up by 26% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.